Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I): wherein Y 1 represents N or C(R 4 ); Y 2 represents N or C(R 5 ); R 4 and R 5 independently represent an alkyl group, a hydrogen atom etc.; one of R 1 and R 2 represents an optionally substituted aryl group, an alkoxy group or an optionally substituted heterocyclic group; the other of R 1 and R 2 represents a haloalkyl group, a cyano group, a halogen atom etc.; and R 3 represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.
1. A nitrogen-containing heterocyclic compound represented by the following general formula (I):
wherein Y 1 represents N or C(R 4 ); Y 2 represents N or C(R 5 ); R 4 and R 5 independently represents an alkyl group which may have a halogen atom, a hydrogen atom, a halogen atom, a cyano group or an alkoxy group; one of R 1 and R 2 represents an haloalkyl group, a cyano group, a carbamoyl group or a halogen atom; the other of R 1 and R 2 represents an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom, wherein the substituents on the aryl group of R 1 or R 2 may form a ring selected from the group consisting of a dioxolane and a dioxane, an alkoxy group or a heterocyclic group selected from the group consisting of a thienyl, thiazolyl or pyrrolyl group which may be substituted by an alkyl group or a halogen atom; and R 3 represents a 5-tetrazolyl group or a carboxy group; and with the proviso that when Y 2 represents CR 5 , Y 2 may form, together with R 2 , a benzene or pyridine ring which may have a haloalkyl group, a halogen atom, a cyano group or an alkoxy group as a substituent, and the neighboring substituents on the benzene or pyridine ring may form a ring selected from the group consisting of a diaxololane and a dioxane, or a pharmaceutically acceptable salt thereof.
2. A nitrogen-containing heterocyclic compound as claimed in claim 1 represented by the following general formula (I-A) or (I-B):
wherein R 4a and R 5a independently represent a hydrogen atom or an alkyl group;
one of R 1a and R 2a represents a haloalky group, a cyano group or a halogen atom;
the other of R 1a and R 2a represents an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom, wherein the substituents on the aryl group of R 1a or R 2a may form a ring selected from the group consisting of a dioxolane and a dioxane, an alkoxy group or a heterocyclic group selected from the group consisting of a thienyl, thiazolyl or pyrrolyl group which may be substituted by an alkyl group or a halogen atom; and
R 3 represents a 5-tetrazolyl group or a carboxy group, or a pharmaceutically acceptable salt thereof.
3. A nitrogen-containing heterocyclic compound as claimed in claim 2 , wherein R 1a represents a cyano group, or a pharmaceutically acceptable salt thereof.
4. A nitrogen-containing heterocyclic compound as claimed in claim 3 , wherein R 2a represents an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom in which some of the substituents may form a ring; an alkoxy group; or a thienyl group which may be substituted by an alkyl group or a halogen atom, or a pharmaceutically acceptable salt thereof.
5. A nitrogen-containing heterocyclic compound as claimed in claim 2 , wherein R 3 represents a carboxy group, or a pharmaceutically acceptable salt thereof.
6. A nitrogen-containing heterocyclic compound as claimed in claim 1 represented by the following general formula (I-C):
wherein y 1C represents N or C (R 4C ) ; Y 3 represents N or C(R 9 ); R 4C and R 9 independently represent an alkyl group, a haloalkyl group, a hydrogen atom, a halogen atom, a cyano group or an alkoxy group;
R 1C represents a cyano group or a carbamoyl group;
R 6 , R 7 and R 8 independently represent an alkyl group, a haloalkyl group, a hydrogen atom, a halogen atom, a cyano group or an alkoxy group; or any of R 6 , R 7 and R 8 may form a ring selected from the group consisting of a dioxolane and a dioxane together with the neighboring substituent; and
R 3 represents a 5-tetrazolyl group or a carboxy group, or a pharmaceutically acceptable salt thereof.
7. A nitrogen-containing heterocyclic compound as claimed in claim 6 , wherein R 1C represents a cyano group, or a pharmaceutically acceptable salt thereof.
8. A nitrogen-containing heterocyclic compound as claimed in claim 6 , wherein R 3 represents a carboxy group, or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a nitrogen-containing heterocyclic compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
10. A pharmaceutical composition as claimed in claim 9 , which is a xanthine oxidase inhibitor.
11. A pharmaceutical composition as claimed in claim 9 , which is an uricosuric agent.
12. A pharmaceutical composition as claimed in claim 9 , which is an agent for the treatment of gout or hyperuricemia.